Actively Recruiting
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Led by Shanghai Junshi Bioscience Co., Ltd. · Updated on 2025-08-21
180
Participants Needed
1
Research Sites
85 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma
CONDITIONS
Official Title
JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 80 years old (inclusive), male or female
- ECOG performance status 0 to 2
- Pathologically diagnosed B-cell Non-Hodgkin's lymphoma expressing CD20 antigen
- At least one measurable lesion as defined by Lugano 2014 response criteria
- Acceptable organ function at screening
You will not qualify if you...
- History of severe allergy to monoclonal antibody therapy or related fusion proteins
- Previous treatment with CD20-CD3 bispecific antibody
- Prior allogeneic hematopoietic stem cell transplantation
- Previous solid organ transplantation
- History of autoimmune diseases
- History of macrophage activation syndrome or hemophagocytic lymphohistiocytosis
- History of progressive multifocal leukoencephalopathy
- Known or suspected central nervous system lymphoma
- Presence of pleural, peritoneal, or pericardial effusion requiring treatment such as drainage or puncture
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
B
Bang.an Peng, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here